Literature DB >> 22737266

Quantitative methods for assessing drug synergism.

Ronald J Tallarida1.   

Abstract

Two or more drugs that individually produce overtly similar effects will sometimes display greatly enhanced effects when given in combination. When the combined effect is greater than that predicted by their individual potencies, the combination is said to be synergistic. A synergistic interaction allows the use of lower doses of the combination constituents, a situation that may reduce adverse reactions. Drug combinations are quite common in the treatment of cancers, infections, pain, and many other diseases and situations. The determination of synergism is a quantitative pursuit that involves a rigorous demonstration that the combination effect is greater than that which is expected from the individual drug's potencies. The basis of that demonstration is the concept of dose equivalence, which is discussed here and applied to an experimental design and data analysis known as isobolographic analysis. That method, and a related method of analysis that also uses dose equivalence, are presented in this brief review, which provides the mathematical basis for assessing synergy and an optimization strategy for determining the dose combination.

Entities:  

Keywords:  additivity; dose-effect relation; drug combinations; isoboles; optimal dose strategy; subadditivity; synergism

Year:  2011        PMID: 22737266      PMCID: PMC3379564          DOI: 10.1177/1947601912440575

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  25 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

2.  Isobolographic analysis for combinations of a full and partial agonist: curved isoboles.

Authors:  Yury Grabovsky; Ronald J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2004-06-02       Impact factor: 4.030

Review 3.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 4.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

5.  Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine.

Authors:  R J Tallarida; H L Kimmel; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1997-10       Impact factor: 4.530

Review 6.  The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.

Authors:  Ronald J Tallarida; Robert B Raffa
Journal:  Pharmacol Ther       Date:  2010-05-28       Impact factor: 12.310

7.  Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught; H I Jacoby; N Selve
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030

8.  Isobolographic superadditivity between delta and mu opioid agonists in the rat depends on the ratio of compounds, the mu agonist and the analgesic assay used.

Authors:  J U Adams; R J Tallarida; E B Geller; M W Adler
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

9.  Self-administration of drug mixtures by monkeys: combining drugs with comparable mechanisms of action.

Authors:  W L Woolverton; Zhixia Wang; Theresa Vasterling; F Ivy Carroll; Ronald Tallarida
Journal:  Psychopharmacology (Berl)       Date:  2007-11-20       Impact factor: 4.530

10.  Mutual potentiation of antinociceptive effects of morphine and clonidine on motor and sensory responses in rat spinal cord.

Authors:  G L Wilcox; K H Carlsson; A Jochim; I Jurna
Journal:  Brain Res       Date:  1987-03-03       Impact factor: 3.252

View more
  89 in total

1.  Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice.

Authors:  Molly S Crowe; Emma Leishman; Matthew L Banks; Ramesh Gujjar; Anu Mahadevan; Heather B Bradshaw; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

2.  Mephedrone interactions with cocaine: prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats.

Authors:  Ryan A Gregg; Christopher S Tallarida; Allen B Reitz; Scott M Rawls
Journal:  Behav Pharmacol       Date:  2013-12       Impact factor: 2.293

3.  miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.

Authors:  Xiaojie Yu; Yiqiang Zhang; Xiuye Ma; Alexander Pertsemlidis
Journal:  Cancer Lett       Date:  2018-04-13       Impact factor: 8.679

4.  A central composite rotatable design (CCRD) approach to study the combined effect of antimicrobial agents against bacterial pathogens.

Authors:  Fernanda Godoy Santos; Layanne Andrade Mendonça; Hilário Cuquetto Mantovani
Journal:  World J Microbiol Biotechnol       Date:  2015-06-17       Impact factor: 3.312

5.  Combined diazepam and MK-801 therapy provides synergistic protection from tetramethylenedisulfotetramine-induced tonic-clonic seizures and lethality in mice.

Authors:  Michael P Shakarjian; Mahil S Ali; Jana Velíšková; Patric K Stanton; Diane E Heck; Libor Velíšek
Journal:  Neurotoxicology       Date:  2015-03-14       Impact factor: 4.294

6.  Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models.

Authors:  Jing Tian; Yuanzeng Min; Zachary Rodgers; Kin Man Au; C Tilden Hagan; Maofan Zhang; Kyle Roche; Feifei Yang; Kyle Wagner; Andrew Z Wang
Journal:  J Mater Chem B       Date:  2017-07-05       Impact factor: 6.331

7.  Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.

Authors:  Alessandro Prete; Agnes S Lo; Peter M Sadow; Swati S Bhasin; Zeus A Antonello; Danica M Vodopivec; Soumya Ullas; Jennifer N Sims; John Clohessy; Ann M Dvorak; Tracey Sciuto; Manoj Bhasin; Joanne E Murphy-Ullrich; Jack Lawler; S Ananth Karumanchi; Carmelo Nucera
Journal:  Clin Cancer Res       Date:  2018-08-03       Impact factor: 12.531

8.  Impact of Antifungal Compounds on Viability and Anti-Aspergillus Activity of Human Natural Killer Cells.

Authors:  Stanislaw Schmidt; Ralf Schubert; Lars Tramsen; Thomas Lehrnbecher
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.